ProQR Therapeutics NV Stock Quote PRQR - Stock Price, News, Charts, Message Board, Trades

Register for real-time alerts, custom portfolio, and market movers

Get Started

Home
Investing
Stocks
USA
NASDAQ
ProQR Therapeutics NV (PRQR) Quote

ProQR Therapeutics NV (PRQR)

2.02

0.02

(1.00%)

Closed April 24 4:00PM

Delayed by 15 minutes

2.0986

0.0786

(3.89%)

After Hours: 7:56PM

Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Current Price

2.0986

Bid

1.95

Ask

2.14

Volume

185,505

1.99 Day's Range 2.12

1.11 52 Week Range 3.29

Market Cap

Previous Close

2.00

Open

2.01

Last Trade

Last Trade Time

Financial Volume

$ 381,811

VWAP

2.0582

Average Volume (3m)

207,548

Shares Outstanding

81,354,592

Dividend Yield

-

PE Ratio

-5.90

Earnings Per Share (EPS)

-0.35

Revenue

6.59M

Net Profit

-28.12M

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.proqr.com

Headquarters

Leiden, South Holland, Nld

Founded

1970

ProQR Therapeutics NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRQR. The last closing price for ProQR Therapeutics NV was $2. Over the last year, ProQR Therapeutics NV shares have traded in a share price range of $ 1.11 to $ 3.29.

ProQR Therapeutics NV currently has 81,354,592 shares outstanding. The market capitalization of ProQR Therapeutics NV is $165.96 million. ProQR Therapeutics NV has a price to earnings ratio (PE ratio) of -5.90.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.0586	2.87254901961	2.04	2.12	1.81	167242	1.94413912	CS
4	-0.2714	-11.4514767932	2.37	2.49	1.81	150148	2.12497456	CS
12	-0.0114	-0.54028436019	2.11	2.7	1.81	207548	2.14029501	CS
26	0.7986	61.4307692308	1.3	3.29	1.11	260489	2.0422956	CS
52	-0.1814	-7.95614035088	2.28	3.29	1.11	266722	1.87886017	CS
156	-4.1314	-66.3146067416	6.23	9.09	0.53	815347	2.82923262	CS
260	-9.1414	-81.3291814947	11.24	13.28	0.53	746108	4.53017141	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NIVFNewGenIvf Group Ltd	$ 2.23 (74.22%)	137.08M
MTCMMTec Inc	$ 2.24 (43.59%)	6.07M
OPRTOportun Financial Corporation	$ 3.16 (40.44%)	11.71M
SHIMShimmick Corporation	$ 3.05 (35.56%)	1.19M
HKITHitek Global Inc	$ 1.35 (32.35%)	411.78k
ABEOAbeona Therapeutics Inc	$ 3.39 (-53.94%)	5.51M
GWAVGreenwave Technology Solutions Inc	$ 0.0696 (-44.89%)	37.05M
LICNLichen China Limited	$ 0.56 (-42.19%)	6.61M
MLECMoolec Science SA	$ 1.71 (-30.77%)	3.16M
VAXXVaxxinity Inc	$ 0.1971 (-26.89%)	2.11M
CYNCYNGN Inc	$ 0.113 (-6.61%)	326.58M
PEGYPineapple Energy Inc	$ 0.0561 (22.49%)	185.74M
SQQQProShares UltraPro Short QQQ	$ 11.91 (-4.49%)	139.15M
NIVFNewGenIvf Group Ltd	$ 2.23 (74.22%)	137.08M
TSLATesla Inc	$ 144.68 (1.85%)	124.55M

PonkenPlonken

PonkenPlonken 6 days ago

added 2.01 hoping for love from LLY, 4bln in milestones.

glenn1919

glenn1919 1 month ago

PRQR.....................................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 1 month ago

PRQR............................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2 months ago

Monksdream

Monksdream 7 months ago

AJ Freely

AJ Freely 9 months ago

$PRQR - 👆Up 7.3% Pre-Market/ Current Price $1.65
Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

KeepOn

KeepOn 1 year ago

Alan Brown

Alan Brown 1 year ago

Alan Brown

Alan Brown 1 year ago

subslover

subslover 1 year ago

Eli Lilly sends ProQR 35% higher after expanding RNA editing deal

https://seekingalpha.com/news/3919739-prqr-stock-surges-as-eli-lilly-expands-rna-editing-deal

TommyBoyTrader9460

TommyBoyTrader9460 1 year ago

$PRQR Strong break up the chart..on watch next week

https://stockcharts.com/c-sc/sc?s=PRQR&p=D&b=5&g=0&i=0&r=1668863394516

MADDSTACKER

MADDSTACKER 2 years ago

Time for a bounce … I hope :)

KeepOn

KeepOn 2 years ago

$4 is the lowest consensus I can find here:
https://etfdailynews.com/news/proqr-therapeutics-nasdaqprqr-pt-lowered-to-8-00/

What say you?

Also, when do we know it stopped dropping?

jaggerxj6

jaggerxj6 2 years ago

....looking for a 80 cent deadcat bounce?????

swampboots

swampboots 2 years ago

PRQR holding steady in market colapse odds are for up in 3 days.

swampboots

swampboots 2 years ago

PRQR 1.38 start.

stockguard

stockguard 2 years ago

ProQR Therapeutics SCHEDULE 13G 02/04/2022
Amended: It`s a boy!!!!!!!!! Really they only missed a 100,000 shares bought by Wellington Management Group LLP that is runs a lot of Vanguard and ETF funds.....
https://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++ProQR+Therapeutics+N.V.++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/19559743.html

JohnLocke101

JohnLocke101 2 years ago

JohnLocke101

JohnLocke101 2 years ago

Important area here for PRQR in the 8.40ish resistance. Hopefully we can get a volume surge.

JohnLocke101

JohnLocke101 2 years ago

Some Nov/Dec call options with $10 strike traded today.. time for the pps to get up there. Looking stable going into 2022. Q 1/2 will be big.

JohnLocke101

JohnLocke101 2 years ago

Im liking the setup. Come on PRQR, make the move. Bollinger says we’re close.

MADDSTACKER

MADDSTACKER 2 years ago

Lilly earnings tomorrow wonder if we get a mention

JohnLocke101

JohnLocke101 3 years ago

Investment Case On ProQR Therapeutics Gets More Enticing

murocman

murocman 3 years ago

Looks like the high 7’s are even better! Man somebody took the air out of this balloon today.

Murocman

JohnLocke101

JohnLocke101 3 years ago

Low $8’s is a great place to add, me thinks.

MADDSTACKER

MADDSTACKER 3 years ago

JohnLocke101

JohnLocke101 3 years ago

Yep. Editas data validated PRQR. Continued new highs coming.

Good Luck!

MADDSTACKER

MADDSTACKER 3 years ago

News out , nice volume

MADDSTACKER

MADDSTACKER 3 years ago

JohnLocke101

JohnLocke101 3 years ago

I see indications that PRQR is about to make a move up. We’ll see..

MADDSTACKER

MADDSTACKER 3 years ago

Mind if I ask what you saw ?

JohnLocke101

JohnLocke101 3 years ago

I think options activity is getting interesting.

MADDSTACKER

MADDSTACKER 3 years ago

What do you think of these guys ? Seems like $50 at some point ?

JohnLocke101

JohnLocke101 3 years ago

Oops. Sorry about that.

Oligonucleotides to treat eye disease

MADDSTACKER

MADDSTACKER 3 years ago

Is that for prqr ?

JohnLocke101

JohnLocke101 3 years ago

MADDSTACKER

MADDSTACKER 3 years ago

Anyone else felling a break out coming ?

JohnLocke101

JohnLocke101 3 years ago

Eli Lilly takes 5.6% stake in PRQR according to 13g

JohnLocke101

JohnLocke101 3 years ago

Personally, I think it gets swooped up before then.

Anyone else load up under $8 for another round?

Good Luck!

MADDSTACKER

MADDSTACKER 3 years ago

Need some 2023 calls

JohnLocke101

JohnLocke101 3 years ago

Been fun today. Even as quiet as this board is.

Sub 8 now, they’re giving it away, so adding big.. again.

Good Luck!

JohnLocke101

JohnLocke101 3 years ago

“QR-421a was observed to be well tolerated at all doses in participants with exon 13 mutations in USH2A. QR-421a demonstrated encouraging evidence of disease stabilization in visual acuity and clinically significant improvements in retinal sensitivity, supported by objective retinal structural imaging data, after a single dose compared with UE and SE. An open-label extension trial is planned to follow up the Stellar trial participants, and 2 Phase 2/3 trials are planned."

JohnLocke101

JohnLocke101 3 years ago

JohnLocke101

JohnLocke101 3 years ago

ProQR Therapeutics teams up with Eli Lilly in potential $1.25B research collaboration

JohnLocke101

JohnLocke101 3 years ago

Added the dip, sub $7

JohnLocke101

JohnLocke101 3 years ago

Vicious little eod rally. Hrmm..

JohnLocke101

JohnLocke101 3 years ago

Looking good leading up to the fireside chat.

JohnLocke101

JohnLocke101 3 years ago

Is it finally time to take the next leg up? Looking promising..

Microlytics

Microlytics 3 years ago

Get ready boys and girls, this can rip at any time

Microlytics

Microlytics 3 years ago

ProQR Therapeutics NV

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions